Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 4/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.44 |
| ▸ | HBB | P68871 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20381756 | 0.87 | MAPK1 (0.47) | ALDH1A1KDM4EHSD17B10MEN1BRCA1 | |
| SCHEMBL3288442 | 0.85 | KDM4E (0.48) | ALDH1A1KDM4EHSD17B10MEN1BRCA1 | |
| SCHEMBL1013370 | 0.85 | KDM4E (0.44) | NR1H2NR1H3ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL30657584 | 0.85 | KDM4E (0.44) | NR1H2NR1H3ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL18993123 | 0.84 | NPC1 (0.43) | ALDH1A1KDM4EHSD17B10MEN1BRCA1 | |
| SCHEMBL15096330 | 0.82 | EGLN1 (0.46) | ALDH1A1KDM4EHSD17B10MEN1BRCA1 | |
| SCHEMBL1037552 | 0.82 | FAAH (0.47) | NR1H2NR1H3ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL27209670 | 0.82 | ALDH1A1 (0.41) | NR1H2NR1H3ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL27233665 | 0.82 | NR1H2 (0.46) | NR1H2NR1H3ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL27233678 | 0.82 | PPARG (0.43) | NR1H2NR1H3ALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115186-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | NEUROPN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260102393-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROPN THERAPEUTICS INC. (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260083718-A1 | PIPERIDINE UREA DERIVATIVES FOR OBESITY THERAPY | ASTRIZI BIO, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-12121515-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | NeuroPn Therapeutics, Inc. (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240294516-A1 | PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | NeuroPn Therapeutics, Inc. (US) | 2024-09-05 | — | — | US | disclosed |
| US-11998538-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | NEUROPN THERAPEUTICS (US) | 2024-06-04 | — | — | US | disclosed |
| US-11998538-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | NEUROPN THERAPEUTICS (US) | 2024-06-04 | — | — | US | disclosed |
| US-11998538-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | NEUROPN THERAPEUTICS (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240139172-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | NeuroPn Therapeutics, Inc. (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240140930-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROPN THERAPEUTICS INC. (US) | 2024-05-02 | — | — | US | disclosed |
| WO-2024073648-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | NeuroPn Therapeutics, Inc. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240075023-A1 | PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | NeuroPn Therapeutics, Inc. (US) | 2024-03-07 | — | — | US | disclosed |
| EP-4323341-A1 | PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Neuropn Therapeutics, LLC (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20220354839-A1 | PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | NEUROPN THERAPEUTICS, LLC (US) | 2022-11-10 | — | — | US | disclosed |
| US-9682953-B2 | Amide compounds, compositions and applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-06-20 | — | — | US | disclosed |
| US-8044052-B2 | Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis | PFIZER INC. (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2076508-B1 | BIARYL ETHER UREA COMPOUNDS | PFIZER PROD INC (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2076508-A2 | BIARYL ETHER UREA COMPOUNDS | Pfizer Products Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20080261941-A1 | Biaryl Ether Urea Compounds | Jazz Pharmaceuticals Therapeutics, Inc. | 2008-10-23 | — | — | US | disclosed |
| WO-2008047229-A2 | BIARYL ETHER UREA COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115186-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | CHEK1, CHEK2, BUB3 | NR1H2 1048/4885NR1H3 1083/4885ALDH1A1 363/4885 |
| US-20240139172-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | PDCD1, TP53, CHEK2 | NR1H2 2997/4885NR1H3 3228/4885ALDH1A1 564/4885 |
| US-20260083718-A1 | PIPERIDINE UREA DERIVATIVES FOR OBESITY THERAPY | GLP1R, GIPR, GPR119 | NR1H2 99/4885NR1H3 130/4885ALDH1A1 1688/4885 |
| US-20260102393-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, PARK7, FAAH | NR1H2 141/4885NR1H3 187/4885ALDH1A1 201/4885 |
| US-20240075023-A1 | PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, HPGDS | NR1H2 110/4885NR1H3 122/4885ALDH1A1 241/4885 |
| US-20220354839-A1 | PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, HPGDS | NR1H2 110/4885NR1H3 122/4885ALDH1A1 241/4885 |
| US-12121515-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, HPGDS | NR1H2 110/4885NR1H3 122/4885ALDH1A1 241/4885 |
| US-20080261941-A1 | Biaryl Ether Urea Compounds | FAAH, FAAH2, LIPC | NR1H2 52/4885NR1H3 44/4885ALDH1A1 360/4885 |
| US-20240140930-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | PRPH, EPHX1, BCHE | NR1H2 287/4885NR1H3 356/4885ALDH1A1 423/4885 |
| US-11998538-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, HPGDS | NR1H2 110/4885NR1H3 122/4885ALDH1A1 241/4885 |
| US-20240294516-A1 | PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, HPGDS | NR1H2 110/4885NR1H3 122/4885ALDH1A1 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.